News

A glimpse at what to expect from Dermatology Times this week.

ICYMI, some of this week’s featured content includes videos with expert KOLs on climate change and acne. Plus, stories on intermittent fasting for psoriasis, consumers and sunscreen labels, the link between hair loss and COVID-19 severity, and more.

In part two of our interview with Misha Rosenbach, MD, he reveals what kind of skin manifestations are on the rise due to global warming and how dermatologists can help fight against climate change.

This week’s edition of The Mainstream Patient features stories on eyelash growth serums, skin fasting, treating hidradenitis suppurativa scars, plus more.

A glimpse at what to expect from Dermatology Times this week.

Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of May.

In this special edition of our "Meet the Aesthetic Expert" column, Will Kirby, DO, FAOCD, talks with board-certified, fellowship-trained dermatologist Deanne Mraz Robinson, MD, about her just announced role as chief medical officer of Ideal Image, the struggles regarding BDD patients, and the expanding role of allied healthcare providers.

This week’s edition of The Mainstream Patient features stories on skin care pilling, mandelic acid, fungal acne, hyperpigmentation, and more.

A glimpse at what to expect from Dermatology Times this week.

ICYMI, some of this week’s featured content includes late breaking research results coming out of AAD VMX 2021. Plus, stories on sun protection to prevent skin cancer, microneedling strategies, and more.

Catch up on all of the latest news coming out of the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021).

This week’s edition of The Mainstream Patient features stories on cryptocurrency for cosmetic procedures, tattoo removal, full-size sunscreen in carry-on bags, using ice on the face, plus more.

Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.

A glimpse at what to expect from Dermatology Times this week.

Phase 3 trial of Otezla shows improved measures of disease severity in adults with mild to moderate plaque psoriasis regardless of their Body Surface Area affected by the disease.

Incyte's Phase 2 study evaluating ruxolitinib cream for vitiligo meets primary endpoint, shows improvement in body and facial repigmentation compared to placebo.

Experts in core dermatological specialties share their insights on the game-changing research and innovation that advancing skin disease management and patient care.

Tremfya phase 3 data shows skin clearance rates were maintained at 5 years with 55.5% of patients achieving an IGA score of 0% and 53% achieving PASI 100 response in VOYAGE 2 trial.

The American Academy of Dermatology Announced the results from its annual election, with 2 officers and 4 board members assuming their new positions in March 2022.

In this video interview, Melissa Stenstrom, MD, previews what she is most excited about at the upcoming American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021

This week’s edition of The Mainstream Patient features stories on the skin barrier, cellulite treatments, tranexamic acid, sun poisoning symptoms, plus more.

A glimpse at what to expect from Dermatology Times this week.

ICYMI, some of this week’s featured content includes new safety data on baricitinib for atopic dermatitis, low malignancy risk for secukinumab in psoriasis, new columns, video coverage from the Inaugural Symposium for Inflammatory Skin Disease, plus more.

In this video interview, Linda Stein Gold, MD, discusses her recent presentation at the Inaugural SISD regarding using topicals for atopic dermatitis.

In this month's Cosmetic Conundrums column, Dermatology Times Chief Medical Editor Zoe Diana Draelos, MD, discusses how to solve common challenges associated with pierced earrings.

This week’s edition of The Mainstream Patient features stories on fraxel lasers, microcurrent facials, perioral dermatitis, brow lifts, plus more.

Given the high prevalence of Kawasaki disease during the pandemic, Japanese investigators determined that droplet or contact transmission of pathogens is likely not a major route causing the development of the disease.

A glimpse at what to expect from Dermatology Times this week.

ICYMI, some of this week’s featured content includes stories on the cyberwar against health care practices, the link between oxytocin and skin aging, baricitinib for alopecia areata, plus more.

Timber Pharmaceuticals's phase 2b trial of isotretinoin for congenital ichthyosis (CI) has reached 50% enrollment.